Catapresan 25 mikrog Norja - norja - Statens legemiddelverk

catapresan 25 mikrog

boehringer ingelheim international gmbh - klonidinhydroklorid - tablett, drasjert - 25 mikrog

Nytox vet 1000 mg/ g Norja - norja - Statens legemiddelverk

nytox vet 1000 mg/ g

naqua ltd - trikainmesilat - pulver til behandlingsoppløsning til fisk - 1000 mg/ g

Tricaine Pharmaq 1000 mg/ g Norja - norja - Statens legemiddelverk

tricaine pharmaq 1000 mg/ g

pharmaq as, overhalla - trikainmesilat - pulver til behandlingsoppløsning til fisk - 1000 mg/ g

Isemid Euroopan unioni - norja - EMA (European Medicines Agency)

isemid

ceva santé animale - torasemide - high-ceiling diuretika, sulfonamider, vanlig - hunder - for behandling av kliniske tegn er relatert til hjertesvikt hos hund, blant annet lungeødem.

Nyvigan kombipakning 100000 IE/ g / 100000 IE Norja - norja - Statens legemiddelverk

nyvigan kombipakning 100000 ie/ g / 100000 ie

avia pharma ab - nystatin - salve, vaginaltablett - 100000 ie/ g / 100000 ie

Profender 96 mg / 24 mg Norja - norja - Statens legemiddelverk

profender 96 mg / 24 mg

2care4 aps - prazikvantel / emodepsid - påflekkingsvæske, oppløsning - 96 mg / 24 mg

Diane 2 mg / 35 mikrog Norja - norja - Statens legemiddelverk

diane 2 mg / 35 mikrog

bayer ab - solna - cyproteronacetat / etinyløstradiol - tablett, drasjert - 2 mg / 35 mikrog

Alofisel Euroopan unioni - norja - EMA (European Medicines Agency)

alofisel

takeda pharma a/s - darvadstrocel - rektal fistel - immunsuppressive - alofisel er angitt for behandling av komplekse perianale fistler hos voksne pasienter med ikke-aktive/mildt aktiv luminal crohns sykdom, når fistler har vist en utilstrekkelig respons på minst en konvensjonell eller biologisk terapi. alofisel bør brukes etter condition av fistel.

Dasatinib Accord Euroopan unioni - norja - EMA (European Medicines Agency)

dasatinib accord

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Dasatinib Accordpharma Euroopan unioni - norja - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.